Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.
about
Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic optionsMicelle-like nanoparticles as carriers for DNA and siRNAIn vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.Myricetin induces apoptosis and enhances chemosensitivity in ovarian cancer cells.Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis.Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcomaP-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cellsElevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells.Expression and Function of CD44 in Epithelial Ovarian CarcinomaHDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomideMRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor.A novel uPAg-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitroMultifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.Rack1 Mediates the Interaction of P-Glycoprotein with Anxa2 and Regulates Migration and Invasion of Multidrug-Resistant Breast Cancer CellsMetastasis of ovarian cancer is mediated by kallikrein related peptidases.The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis.Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Tissue engineering concept in the research of the tumor biology.Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.Involvement of urokinase-type plasminogen activator system in cancer: an overview.CD44 is a biomarker associated with human prostate cancer radiation sensitivity.Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts.Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe.Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression.Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.
P2860
Q26748666-F2A0D71A-36F1-4121-A36F-D94FDC0A5DE8Q27001558-D90D3051-41FC-4D9A-9207-E35A48550F64Q28482047-2E5024AE-C51E-4F7F-8EC3-93862FEE6CFEQ31133958-CF83F34C-A9D4-4CB0-B6FE-9023F182E3F8Q33750813-57BE0D8B-1774-4BC0-943B-FF428DEF71E2Q34309819-5C6C1FCF-7F59-4441-8F4A-F4723ECE43D1Q34602948-CEE3A28F-2C09-44E5-B277-E7F5FB480F65Q34874835-5F2460E0-4CD0-4896-9330-2590243682B4Q35017209-E036C540-FCFD-419C-9947-E19EB2610979Q35089472-A7F19FDA-BBD4-4C51-A7C9-A61306D87437Q35116847-CAC8FBC4-821F-4146-9CF5-4D6193EB986BQ35227377-5288CCBD-2B98-4D4E-B146-581258456845Q35587385-73F8280F-65A4-460F-8987-0308C2D2BCE3Q35746515-67574629-6163-4E8C-87F3-6E7E3E3466F4Q36174338-15F6DDDD-66C2-4332-86ED-60EF47C1E74BQ36247462-5B60B1D0-3E93-4EA6-8892-30A2B822FBCFQ36409587-F18FE25A-9DB5-429A-9F72-038C75DA3089Q36544516-E0890171-0AB4-4778-99E0-D946EE6C8E7BQ36601950-3A336DCB-2FCA-4D69-813D-50A5A6C9F155Q36791190-735A7C7D-E756-408C-8FD1-A3CE87BC70AEQ37131462-E862848E-65F0-4B96-83A6-D324C7429A5CQ37377476-8E49177C-40CB-43C4-AAEF-800FC7B5013BQ37480184-41275FCF-FA00-4D03-9FA7-382E39505CD3Q37564029-EDCD3591-A0A2-423E-84E1-0DACCD815361Q37801943-631FE9B2-E937-437B-B3BE-74DE3900BA36Q37809871-F98E0898-3771-4814-A4C1-4A0EE6BE2598Q38122201-365AC3BE-8637-4153-9985-05DCB1BD05B3Q38184632-A5B71F6A-7FB5-4DE4-B6F3-6B763CF894ABQ38189275-20ADF8EF-2568-4F39-A24B-C28707413A39Q39467150-78ADB475-273B-48AC-8C79-42D8AF544F75Q39654818-F5C5F886-3121-4501-BDF1-812EC5698E1EQ41561405-7AC01B9E-BFC7-46B4-942E-B5AF24DA4629Q42798231-BD0AF991-4082-48C6-944E-D44BB8013DBEQ42958379-FFE977C0-B823-4681-BCC5-032A754FD7DDQ55396904-45DF888E-5D49-4F78-8F74-6F5D5D7915AF
P2860
Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Coexpression of invasive marke ...... al ovarian cancer progression.
@ast
Coexpression of invasive marke ...... al ovarian cancer progression.
@en
type
label
Coexpression of invasive marke ...... al ovarian cancer progression.
@ast
Coexpression of invasive marke ...... al ovarian cancer progression.
@en
prefLabel
Coexpression of invasive marke ...... al ovarian cancer progression.
@ast
Coexpression of invasive marke ...... al ovarian cancer progression.
@en
P2093
P2860
P356
P1476
Coexpression of invasive marke ...... al ovarian cancer progression.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605185
P407
P577
2009-07-14T00:00:00Z
P5875
P6179
1029980299